Argenica Therapeutics Ltd

Argenica Therapeutics Limited (ASX: AGN) is a clinical-stage biotechnology company focused on developing innovative neuroprotective drugs to reduce brain damage following stroke and other acute brain injuries. Every year, millions of people globally are affected by stroke, which can lead to serious long-term disability and even death. Argenica’s mission is to protect brain cells during and immediately after such events, aiming to significantly improve patient recovery and outcomes.

At the core of Argenica’s pipeline is ARG-007, a novel neuroprotective peptide. Originating from research conducted at The University of Western Australia and the Perron Institute for Neurological and Translational Science, ARG-007 has demonstrated the ability to reduce brain cell death in preclinical studies of stroke, traumatic brain injury, and hypoxic ischaemic encephalopathy. Early clinical trials have shown that ARG-007 is safe and well-tolerated in healthy volunteers, and it is now being evaluated in Phase 2 clinical trials with acute ischaemic stroke patients in Australian hospitals.

Argenica’s goal is to enable the administration of ARG-007 by first responders, protecting brain tissue at the very moment of injury—whether due to stroke or severe trauma. This approach could revolutionise acute brain injury care by minimizing the impact of these life-altering events and enabling better recoveries. The company is also committed to transparency with its investors and stakeholders, regularly providing updates on clinical progress and business developments as it works to bring this vital therapy to market.